Galecto Biotech AB has expanded its investor syndicate and raised a further €5 million to support the development of its small-molecule modulators of the galectin family of proteins. Total capital raised thus far is €10 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
